The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors.
Jennifer Robinson Diamond
Research Funding - Amgen
Neeraj Agarwal
Consultant or Advisory Role - Exelixis (U); Medivation (U)
Honoraria - Dendreon
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Medivation; Novartis; Pfizer; Takeda
Daniel W. Bowles
No relevant relationships to disclose
Elaine Tat Lam
Consultant or Advisory Role - Exelixis
Research Funding - Astellas Pharma; Bayer; Exelixis; Janssen Pharmaceutical
Theresa Louise Werner
Research Funding - Amgen
Benjamin Wu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Erik Rasmussen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Erick Gamelin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Felipe Soto
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gregory R. Friberg
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yu-Nien Sun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Sunil Sharma
Research Funding - Amgen